Active Ingredient History
Neratinib (HKI-272) is a pan-HER inhibitor, this irreversible tyrosine kinase inhibitor binds and inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2 and HER4, which leads to reduced phosphorylation and activation of downstream signaling pathways. Neratinib is a modified form of the discontinued compound pelitinib, and was originally being develoAdditionally, phase II development of oral neratinib as a neoadjuvant therapy for breast cancer, as a second-line therapy for non-small cell lung cancer, and for other solid tumours is also in progress in numerous countries worldwide. ped by Wyeth (later Pfizer). Oral neratinib is awaiting approval as an extended adjuvant therapy for breast cancer in the EU and in the US. Blocking HER2 function by a small molecule kinase inhibitor, such as neratinib, represents an attractive alternate strategy for the growth inhibition of HER2-positive tumours. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (approved 2017)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Central Nervous System Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Epidermal Growth Factor (Phase 1)
ErbB Receptors (Phase 1)
Glioblastoma (Phase 2)
Healthy Volunteers (Phase 1)
Hemangiosarcoma (Phase 2)
Hepatic Insufficiency (Phase 1)
Leukemia (Phase 1/Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1/Phase 2)
Mutation (Phase 1)
Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue